看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
8 E. ~6 ~! ]1 h, X: Y
4 x# \" O) ]/ a+ W( k1 \ K) y# D- U- B! v
Currently available feasibility data for possible combination strategies.
G+ D( [5 C! [0 X) E————————————————————————————————
& t+ p; H+ }, ?$ PCombination Feasibility according to preliminary data 4 A' W2 W( r0 |: U
——————————————————————————————————4 ]5 [2 J0 H3 O
Bevacizumab + sorafenib Yes, reduced dose
L2 T J3 G# Z& S0 i LBevacizumab + sunitinib† No 1 ?* g- {! f: l5 S3 K
Bevacizumab + temsirolimus Yes 4 k. }- O. |6 \. J2 h* R1 @# O
Bevacizumab + everolimus Yes + D4 Y9 {5 t3 Z1 `% d& ^
Sorafenib + sunitinib ? " h. B) I! H* a+ `8 |. D: k' e
Sorafenib + temsirolimus Yes, reduced dose # E& B+ U3 L) o1 {
Sorafenib + everolimus Yes, reduced dose
/ A9 J8 n& s% A& D! O, m+ `! k% s4 ~Sunitinib + temsirolimus† No
( v7 }; h+ I% f/ RSunitinib + everolimus ? , g3 O ^- n# x$ T1 x; j) K: i
Temsirolimus + everolimus ?
4 \: j4 g( c% K/ V$ q1 A————————————————————
/ E9 S& ?( r, d& @4 F! Z†Led to US FDA warning.
$ X5 Q9 C7 P- B4 a8 R: p/ |?: As yet unattempted combination.
0 B) {9 Z4 K: Y |